The 2026 Peptide Tier List

Every few months a new "peptide tier list" circulates on fitness forums — typically authored by people with strong opinions and thin evidence. This one reverses the priority: quality of evidence first, effect size second, internet buzz zero.

Tier S — Clinically validated, large effect

Semaglutide, Tirzepatide. These are the only two peptides in this tier. Phase-3 trials across tens of thousands of patients, FDA approval for both diabetes and obesity, and — in semaglutide's case — documented reductions in major cardiovascular events (SELECT, 2023). Effect size is dominant: 15–22% weight reduction over 68+ weeks. Nothing else is close.

Tier A — Evidence-backed, specific use cases

Tesamorelin. FDA-approved. Consistent 15–20% visceral adipose reduction. Narrower indication than GLP-1s but the strongest evidence for any GHS-class peptide.

GHK-Cu (topical). Decades of cosmetic dermatology research, gene-expression data on ~4,000 human genes, reproducible skin-remodeling effects. Modest effect size for wrinkles, but well-supported.

Tier B — Promising preclinical, limited human data

BPC-157, TB-500. Strong rodent signal for tissue healing. Human evidence is preliminary. Widespread off-label use does not substitute for trial data. FDA's 2023 section 503A listing is a regulatory reality check.

CJC-1295 + Ipamorelin. The best-characterized GHS stack, with documented GH/IGF-1 elevation in small studies. Effect sizes for body composition are modest in trained populations.

Tier C — Interesting science, very early

MOTS-c, Epitalon, Sermorelin. Each has a valid biological rationale and some data, but no robust controlled human trials demonstrating meaningful clinical endpoints. Use is heavily influenced by practitioner tradition rather than evidence.

Tier D — Overhyped, under-evidenced

AOD-9604. The GH 176-191 fragment. Extensive marketing, weak human efficacy data at available doses. Did not meet phase-2b weight-loss endpoints.

PT-141 (bremelanotide for sexual dysfunction). An exception — FDA-approved, works, but falls outside the fitness-peptide conversation it's often bundled with.

The meta-point

Peptide hype moves faster than peptide evidence. The gap between "this molecule works in mice and internet forums say it's transformative" and "this molecule works in a controlled human trial" is enormous. Use that gap to calibrate expectations.

FAQ

What is the safest peptide to start with?

For beginners, Ipamorelin is widely considered the best-tolerated GH secretagogue — it produces clean GH pulses without significant cortisol or prolactin elevation, and side effects are minimal at standard doses (100-200 mcg). For topical use, GHK-Cu has an excellent safety profile with decades of cosmetic use. For gut-specific applications, oral BPC-157 avoids injection entirely. The "safest" depends on your goal — but starting with a single, well-characterized peptide at conservative doses and assessing response before adding complexity is the universal best practice.

Which peptides have the most human clinical data?

Semaglutide and tirzepatide lead by a wide margin — multiple Phase 3 RCTs with tens of thousands of participants and FDA approval. Thymosin Alpha-1 has substantial clinical trial data and is approved in over 35 countries. Cerebrolysin has multiple RCTs for neurological indications and is approved in 40+ countries. Among research peptides, most (BPC-157, TB-500, MOTS-c, Epitalon) have strong preclinical evidence but lack controlled human trials. The evidence gap between pharmaceutical-grade peptides and research peptides is vast.

How often is the peptide tier list updated?

The tier list reflects the evidence landscape as of early 2026. Peptide evidence evolves slowly — moving from Tier C to Tier B requires new clinical trial data, which typically takes 2-5 years to generate. The most likely near-term shifts include retatrutide (moving up as Phase 3 data matures) and potentially BPC-157 (if any of the ongoing investigator-initiated studies report results). We reassess the tier list when meaningful new clinical data is published, not on a fixed calendar.

Why is AOD-9604 rated so low?

AOD-9604 (the modified GH fragment 176-191) failed to meet primary endpoints in its Phase 2b clinical trial for weight loss. Despite this, it remains heavily marketed as a fat-loss peptide based on preclinical data and the theoretical mechanism of isolated lipolysis without GH's metabolic side effects. The gap between the marketing narrative and the clinical evidence is one of the widest in the peptide space. At doses available through research peptide suppliers, the expected fat-loss effect is modest at best.

Are expensive peptides better than cheap ones?

Price does not reliably correlate with efficacy. Semaglutide (expensive as a brand-name pharmaceutical) is genuinely more effective for weight loss than AOD-9604 (inexpensive as a research peptide). However, within the research peptide market, price primarily reflects manufacturing cost and supplier margins rather than product quality. A $30 vial of BPC-157 from a reputable supplier with third-party testing may be identical in quality to a $90 vial from a premium-branded source. The differentiator is testing verification (CoA with HPLC and mass spectrometry), not price.